Cargando…

Conteltinib (CT-707) in patients with advanced ALK-positive non-small cell lung cancer: a multicenter, open-label, first-in-human phase 1 study

BACKGROUND: Conteltinib (CT-707) is a potent second-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) showing promising anti-tumor activities in preclinical studies. This study aimed to assess the safety, pharmacokinetic (PK), and efficacy of conteltinib in patients with AL...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xing, Puyuan, Zhao, Qian, Zhang, Li, Wang, Hanping, Huang, Dingzhi, Hu, Pei, Sun, Yinghui, Shi, Yuankai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9694544/ https://www.ncbi.nlm.nih.gov/pubmed/36424628 http://dx.doi.org/10.1186/s12916-022-02646-0

Ejemplares similares

SY-707, an ALK/FAK/IGF1R inhibitor, suppresses growth and metastasis of breast cancer cells: SY-707 is an ALK/FAK/IGF1R inhibitor
por: Liu, Ping, et al.
Publicado: (2022)

Long‐term effects of crizotinib in ALK‐positive tumors (excluding NSCLC): A phase 1b open‐label study
por: Gambacorti‐Passerini, Carlo, et al.
Publicado: (2018)

Ensartinib in advanced ALK-positive non-small cell lung cancer: a multicenter, open-label, two-staged, phase 1 trial
por: Ma, Yuxiang, et al.
Publicado: (2022)

Intracranial efficacy of alectinib in ALK-positive NSCLC patients with CNS metastases—a multicenter retrospective study
por: Zou, Zihua, et al.
Publicado: (2022)

Envonalkib versus crizotinib for treatment-naive ALK-positive non-small cell lung cancer: a randomized, multicenter, open-label, phase III trial
por: Yang, Yunpeng, et al.
Publicado: (2023)

Single‐center study to determine the safety and efficacy of CT‐707 in Chinese patients with advanced anaplastic lymphoma kinase‐rearranged non‐small‐cell lung cancer
por: Song, Peng, et al.
Publicado: (2020)

PacCYP707A2 negatively regulates cherry fruit ripening while PacCYP707A1 mediates drought tolerance
por: Li, Qian, et al.
Publicado: (2015)

Lorlatinib in ALK- or ROS1-rearranged non-small cell lung cancer: an international, multicenter, open-label phase 1 trial
por: Shaw, Alice T., et al.
Publicado: (2017)

CT-707 overcomes hypoxia-mediated sorafenib resistance in Hepatocellular carcinoma by inhibiting YAP signaling
por: Chen, Zibo, et al.
Publicado: (2022)

Efficacy and safety of brigatinib in ALK-positive non-small cell lung cancer treatment: A systematic review and meta-analysis
por: Xing, Puyuan, et al.
Publicado: (2022)

Impact of crizotinib on long-term survival of ALK-positive advanced non-small-cell lung cancer: A Chinese multicenter cohort study
por: Xing, Puyuan, et al.
Publicado: (2019)

707. Molecular Epidemiology of Clostridioides difficile Colonization in Families with Infants
por: Toltzis, Philip, et al.
Publicado: (2023)

Favorable predictors for survival in advanced ALK‐positive non‐small cell lung cancer patients beyond crizotinib resistance
por: Xu, Haiyan, et al.
Publicado: (2019)

PT707. Transcriptome analysis in Tsc2 heterozygous knockout mice
por: Kasai, Shinya, et al.
Publicado: (2016)

707. QPX9003: Pharmacology of a Novel Polymyxin in Mice and Rats
por: Sabet, Mojgan, et al.
Publicado: (2019)

707. Infective Endocarditis and Medication Assisted Treatment in Opioid Use Disorder
por: Loomis, Katherine, et al.
Publicado: (2020)

A multicenter, open-label, phase III study of Abcertin in Gaucher disease
por: Lee, Beom Hee, et al.
Publicado: (2017)

ALK Inhibitors in the Treatment of ALK Positive NSCLC
por: Khan, Muhammad, et al.
Publicado: (2019)

Therapeutic cancer vaccine: phase I clinical tolerance study of Hu-rhEGF-rP64k/Mont in patients with newly diagnosed advanced non-small cell lung cancer
por: Xing, Puyuan, et al.
Publicado: (2018)

Sequential therapy according to distinct disease progression patterns in advanced ALK-positive non-small-cell lung cancer after crizotinib treatment
por: Xu, Haiyan, et al.
Publicado: (2019)

Systeme T.700 (T.704. T.705 T.706 T.707 T.708) dossier d'installation
por: Debordes, R
Publicado: (1976)

Electron Stimulated Molecular Desorption of a NEG St 707 at Room Temperature
por: Le Pimpec, F, et al.
Publicado: (2001)

707 Rapid Identification of Pathogens Causing Septic Arthritis using FilmArray®
por: Sanderson, Susan K., et al.
Publicado: (2014)

MON-707 Improving Screening for Diabetic Retinopathy in a Resident Based Clinic
por: Tofil, Kathrin Sandra, et al.
Publicado: (2020)

Anti-ALK Antibodies in Patients with ALK-Positive Malignancies Not Expressing NPM-ALK
por: Damm-Welk, Christine, et al.
Publicado: (2016)

A multicenter, open-label, phase III study of Abcertin in Gaucher disease: Erratum
Publicado: (2018)

Vemurafenib in Chinese patients with BRAF(V600) mutation–positive unresectable or metastatic melanoma: an open-label, multicenter phase I study
por: Si, Lu, et al.
Publicado: (2018)

SUMOylation at K(707) of DGCR8 controls direct function of primary microRNA
por: Zhu, Changhong, et al.
Publicado: (2015)

The Role of cheA Genes in Swarming and Swimming Motility of Pseudomonas pseudoalcaligenes KF707
por: Fedi, Stefano, et al.
Publicado: (2016)

Denosumab in Giant Cell Rich Tumors of Bone: An Open-Label Multicenter Phase II Study
por: Lipplaa, Astrid, et al.
Publicado: (2023)

Intracranial and whole-body response of ceritinib in ALK inhibitor-naïve and previously ALK inhibitor-treated patients with ALK-rearranged non-small-cell lung cancer (NSCLC): updated results from the phase 1, multicentre, open-label ASCEND-1 trial
por: Kim, Dong-Wan, et al.
Publicado: (2016)

Value of CT features for predicting EGFR mutations and ALK positivity in patients with lung adenocarcinoma
por: Han, Xiaoyu, et al.
Publicado: (2021)

Efficacy and safety of iruplinalkib (WX-0593) in ALK-positive crizotinib-resistant advanced non-small cell lung cancer patients: a single-arm, multicenter phase II study (INTELLECT)
por: Shi, Yuankai, et al.
Publicado: (2023)

Treatment duration as a surrogate endpoint to evaluate the efficacy of crizotinib in sequential therapy for patients with advanced ALK‐positive non‐small cell lung cancer: A retrospective, real‐world study
por: Yang, Guangjian, et al.
Publicado: (2019)

Daratumumab monotherapy for patients with relapsed or refractory natural killer/T-cell lymphoma, nasal type: an open-label, single-arm, multicenter, phase 2 study
por: Huang, Huiqiang, et al.
Publicado: (2021)

Clinical data from the real world: efficacy of Crizotinib in Chinese patients with advanced ALK-rearranged non-small cell lung cancer and brain metastases
por: Xing, Puyuan, et al.
Publicado: (2016)

Clinical outcome, long‐term survival and tolerability of sequential therapy of first‐line crizotinib followed by alectinib in advanced ALK+NSCLC: A multicenter retrospective analysis in China
por: Zou, Zihua, et al.
Publicado: (2021)

Transcriptome-wide subtyping of pediatric and adult T cell acute lymphoblastic leukemia in an international study of 707 cases
por: Dai, Yu-Ting, et al.
Publicado: (2022)

Pooled safety analyses of ALK-TKI inhibitor in ALK-positive NSCLC
por: Zhu, Qian, et al.
Publicado: (2017)

Role of chemokine-mediated angiogenesis in resistance towards crizotinib and its reversal by anlotinib in EML4-ALK positive NSCLC
por: Wang, Shasha, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_g3vcdmjq0mv8pppsvhidju35b9